Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026

Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for histopathology.

Histopathology·2026

Same author

The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): An overview.

Cancer epidemiology·2026

Same author

Tumour markers and evidence-based pathology.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2026

Same author

Development of a decision tree diagram for classifying study designs in tumour pathology research: a multidisciplinary approach.

The journal of pathology. Clinical research·2025

Same author

The World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Part 2 - Spleen and Thymus.

Acta cytologica·2025

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

KRAS mutation analysis by PCR: a comparison of two methods.

Louise Bolton¹, Anne Reiman², Katie Lucas²

¹Department of Pathology, Queen Alexandra Hospital, Portsmouth, United Kingdom.

|January 9, 2015

Summary

Two KRAS mutation assays, Therascreen ARMS and castPCR, showed excellent correlation for guiding colorectal cancer treatment. While castPCR detected more mutations, both methods are comparable for clinical use.

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Related Experiment Videos

Last Updated: Apr 18, 2026

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Area of Science:

Oncology
Molecular Diagnostics
Genetics

Background:

KRAS mutation assays are crucial companion diagnostics for anti-EGFR therapy in metastatic colorectal cancer.
Validating new diagnostic methods against established ones is essential for clinical adoption.

Purpose of the Study:

To compare the diagnostic equivalence of the Therascreen ARMS assay and the Competitive Allele-Specific TaqMan PCR (castPCR) assay for KRAS mutation analysis in colorectal cancer.

Main Methods:

DNA was extracted from 99 colorectal cancer samples.
Therascreen ARMS and a custom castPCR assay were performed using real-time PCR machines.
Discrepant results were re-tested using newly extracted DNA.

Main Results:

Therascreen identified 37 KRAS mutations, while castPCR identified 38.
CastPCR detected additional mutations (e.g., BRAF V600E) not included in Therascreen.
Excellent correlation was observed between the two methods, with only three initial discrepancies resolved upon re-testing.

Conclusions:

The Therascreen and castPCR assays demonstrate excellent correlation for KRAS mutation analysis.
Despite lower Ct values in castPCR, the difference is not considered clinically significant, indicating comparable clinical utility.